Spirocyclic Dihydropyranopyrimidine KRAS Inhibitors for Mutant KRAS Binding

The patent employs parameter changes by designing spirocyclic dihydropyranopyrimidine compounds with specific molecular structures (Formula I, II, III, IV, V, or A) that alter the binding parameters to KRas, enabling effective inhibition despite KRas's intrinsic resistance to conventional GTPase-activating proteins. The compounds feature specific substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10) and ring structures that modify interaction parameters with KRas to overcome its GTPase activity deficiency.

The spirocyclic dihydropyranopyrimidine compounds act as intermediary molecules that bridge the gap between conventional therapy and KRas inhibition. These compounds directly bind to KRas and modulate its activity, serving as a mediator that overcomes KRas's insensitivity to GTPase-activating proteins by providing an alternative inhibition mechanism through specific molecular recognition and binding.

The patent applies segmentation by dividing the complex challenge of KRas inhibition into manageable structural components. The spirocyclic dihydropyranopyrimidine compounds are designed with segmented structures including a dihydropyranopyrimidine core, spirocyclic moieties, and various substituent groups (R1-R10) that can be independently optimized. This segmentation allows systematic development of KRas inhibitors by modifying individual structural elements to enhance binding affinity and selectivity.

The patent employs composite materials principles by creating spirocyclic dihydropyranopyrimidine compounds that combine multiple functional structural elements into a single therapeutic molecule. The compounds integrate a dihydropyranopyrimidine core with spirocyclic structures and various heterocyclic or hydrocarbon substituents, forming a composite molecular architecture that achieves effective KRas inhibition through synergistic interactions of different structural components.

The patent applies preliminary action by designing spirocyclic dihydropyranopyrimidine compounds that proactively bind to KRas and prevent sustained activation before it can drive cancer progression. The compounds are structured to preemptively inhibit KRas GTPase activity by forming stable complexes with KRas, thereby preventing the prolonged GTP-bound state that leads to uncontrolled cell growth and cancer development.

The patent converts the harmful intrinsic GTPase activity deficiency of KRas into a therapeutic opportunity. By designing compounds that specifically exploit KRas's structural characteristics and binding properties, the spirocyclic dihydropyranopyrimidine compounds transform KRas's resistance to conventional inhibition into a target for selective drug binding, enabling effective treatment of KRas-associated cancers through structure-based drug design.